Stock Market Reviews

MAZE (Maze Therapeutics, Inc.) News

Get the latest news, insights, and market updates on MAZE (Maze Therapeutics, Inc.). Explore the news page 1 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.

• Marc Andreessen’s a16z Invests $465 Million in Navan’s Corporate Spending Platform, According to Recent SEC Filing
  a16z Capital Management, the venture firm founded by Marc Andreessen and Ben Horowitz, committed $465 million to Navan, backing its expansion from corporate travel booking into integrated enterprise spending and payments.
  Feb 18, 2026 - $MAZE
• Maze Therapeutics Chief Medical Officer Sells 15K Shares As Company's Stock Continues to Surge
  Maze Therapeutics has been flourishing as a stock and in its operations, which is one of the reasons its Chief Medical Officer's recent share sale shouldn't raise concerns for investors.
  Feb 16, 2026 - $MAZE
• Maze Therapeutics (MAZE) Valuation Check After Strong 1 Year Shareholder Return
  What is driving interest in Maze Therapeutics right now? Maze Therapeutics (MAZE) has drawn fresh attention after recent trading, with the stock closing at $46.01 and showing mixed short term moves, including a 1 day decline and a modest gain over the past week. See our latest analysis for Maze Therapeutics. For context, Maze Therapeutics has a 30 day share price return of 11.92% and a 90 day share price return of 41.44%, while its 1 year total shareholder return of 283.42% suggests strong...
  Feb 15, 2026 - $MAZE
• Maze Therapeutics Highlights Upcoming MZE829 Kidney Data, Maps Phase 2 Plans for MZE782 at Summit
  Maze Therapeutics (NASDAQ:MAZE) is advancing a genetics-driven approach to drug development, using human genetic analyses to identify gene variants linked to disease and then applying those insights to small-molecule programs focused primarily on kidney and metabolic disorders, CEO Jason Coloma said
  Feb 14, 2026 - $MAZE
• Maze Therapeutics to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026
  SOUTH SAN FRANCISCO, Calif., Feb. 04, 2026 (GLOBE NEWSWIRE) -- Maze Therapeutics, Inc. (Nasdaq: MAZE), a clinical-stage biopharmaceutical company developing small molecule precision medicines for patients with kidney and metabolic diseases, today announced that Jason Coloma, Ph.D., chief executive officer of Maze Therapeutics, will present at the Guggenheim Emerging Outlook: Biotech Summit 2026 on Wednesday, February 11, 2026 at 3:00 p.m. ET. A live webcast of the event will be available in the
  Feb 4, 2026 - $MAZE
• Maze Therapeutics SVP Sells 5,000 Shares Amid Historic First Year for the Company's Stock
  Maze Therapeutics' Senior Vice President of Finance sold shares towards the end of January 2026, all while the company's stock had one of the best first-year performances of a biopharmaceutical company.
  Feb 1, 2026 - $MAZE
• What to Know About One Maze Insider's $3 Million Stock Sale as Shares Surge 150%
  This clinical-stage biotech focused on precision medicines reported significant insider selling, according to recent SEC filings.
  Jan 8, 2026 - $MAZE
• Maze Therapeutics to Participate in the 44th Annual J.P. Morgan Healthcare Conference
  SOUTH SAN FRANCISCO, Calif., Jan. 05, 2026 (GLOBE NEWSWIRE) -- Maze Therapeutics, Inc. (Nasdaq: MAZE), a clinical-stage biopharmaceutical company developing small molecule precision medicines for patients with kidney and metabolic diseases, today announced that Jason Coloma, Ph.D., chief executive officer of Maze Therapeutics, will present at the 44th Annual J.P. Morgan Healthcare Conference on Monday, January 12, 2026 at 8:15 a.m. PT. A live webcast of the event will be available in the Investo
  Jan 5, 2026 - $MAZE
• We Think Maze Therapeutics (NASDAQ:MAZE) Can Easily Afford To Drive Business Growth
  Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
  Dec 22, 2025 - $MAZE
• Evaluating Maze Therapeutics (MAZE): Is the Current Valuation Justified After Recent Volatility?
  Maze Therapeutics (MAZE) shares have seen some fairly wide swings lately. The company remains a niche player in the biotech sector. Investors have noticed the recent uptick in the stock’s month performance. See our latest analysis for Maze Therapeutics. Maze Therapeutics’ recent 1-day share price return of 6.6% stands out against a sharp 8.3% loss earlier in the week, showing how momentum can shift quickly. Even so, the stock has climbed more than 120% over the past 90 days, indicating some...
  Nov 11, 2025 - $MAZE